TenNor Therapeutics secures 100% shareholder backing for all six AGM resolutions

Bulletin Express06-29

TenNor Therapeutics (Suzhou) Limited recorded unanimous shareholder support for every motion tabled at its 2025 annual shareholders’ meeting (ASM) held on 29 June 2026 in Suzhou, Jiangsu.

The poll-based voting covered six ordinary resolutions, each receiving 17.10 million votes in favour—representing 100.00% of votes cast and 32.68% of the company’s total issued share capital. No votes were recorded against or as abstentions.

Key resolutions approved: • 2025 work report of the Board of Directors. • 2025 performance report of independent non-executive directors. • 2025 annual financial report. • 2025 profit distribution plan. • Remuneration plan for the current Board session. • Engagement of the Company’s auditor for FY 2026.

As at the meeting date, TenNor had 52.33 million H shares in issue, with no treasury shares outstanding.

Executive Director and Chairman Dr. Ma Zhenkun presided over the meeting; attending directors included Dr. Song Gaoguang, Dr. Li Leping and Dr. Ni Lin. Independent non-executive director Mr. Lee Wai Kong, Albert was absent due to official duties. Tricor Investor Services Limited and two shareholder representatives acted as scrutineers, validating the poll results.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1162988284?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-29 20:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162988284","market":"us","top_or_hot":-1,"title":"TenNor Therapeutics secures 100% shareholder backing for all six AGM resolutions","media":"Bulletin Express","content":"<p>TenNor Therapeutics (Suzhou) Limited recorded unanimous shareholder support for every motion tabled at its 2025 annual shareholders’ meeting (ASM) held on 29 June 2026 in Suzhou, Jiangsu.</p>\n<p>The poll-based voting covered six ordinary resolutions, each receiving 17.10 million votes in favour—representing 100.00% of votes cast and 32.68% of the company’s total issued share capital. No votes were recorded against or as abstentions.</p>\n<p>Key resolutions approved:  \n• 2025 work report of the Board of Directors.  \n• 2025 performance report of independent non-executive directors.  \n• 2025 annual financial report.  \n• 2025 profit distribution plan.  \n• Remuneration plan for the current Board session.  \n• Engagement of the Company’s auditor for FY 2026.</p>\n<p>As at the meeting date, TenNor had 52.33 million H shares in issue, with no treasury shares outstanding.</p>\n<p>Executive Director and Chairman Dr. Ma Zhenkun presided over the meeting; attending directors included Dr. Song Gaoguang, Dr. Li Leping and Dr. Ni Lin. Independent non-executive director Mr. Lee Wai Kong, Albert was absent due to official duties. Tricor Investor Services Limited and two shareholder representatives acted as scrutineers, validating the poll results.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TenNor Therapeutics secures 100% shareholder backing for all six AGM resolutions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTenNor Therapeutics secures 100% shareholder backing for all six AGM resolutions\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-29 20:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TenNor Therapeutics (Suzhou) Limited recorded unanimous shareholder support for every motion tabled at its 2025 annual shareholders’ meeting (ASM) held on 29 June 2026 in Suzhou, Jiangsu.</p>\n<p>The poll-based voting covered six ordinary resolutions, each receiving 17.10 million votes in favour—representing 100.00% of votes cast and 32.68% of the company’s total issued share capital. No votes were recorded against or as abstentions.</p>\n<p>Key resolutions approved:  \n• 2025 work report of the Board of Directors.  \n• 2025 performance report of independent non-executive directors.  \n• 2025 annual financial report.  \n• 2025 profit distribution plan.  \n• Remuneration plan for the current Board session.  \n• Engagement of the Company’s auditor for FY 2026.</p>\n<p>As at the meeting date, TenNor had 52.33 million H shares in issue, with no treasury shares outstanding.</p>\n<p>Executive Director and Chairman Dr. Ma Zhenkun presided over the meeting; attending directors included Dr. Song Gaoguang, Dr. Li Leping and Dr. Ni Lin. Independent non-executive director Mr. Lee Wai Kong, Albert was absent due to official duties. Tricor Investor Services Limited and two shareholder representatives acted as scrutineers, validating the poll results.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06872","symbol_name":"丹诺医药-B","start_time":0,"source_url":"","article_id":"1162988284","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162988284","pubTimestamp":1782735792,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"TenNor Therapeutics (Suzhou) Limited recorded unanimous shareholder support for every motion tabled at its 2025 annual shareholders’ meeting (ASM) held on 29 June 2026 in Suzhou, Jiangsu. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06872":"丹诺医药-B"},"translate_title":"TenNor Therapeutics获得所有六项年度股东大会决议100%股东支持","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06872":1},"content_text":"TenNor Therapeutics (Suzhou) Limited recorded unanimous shareholder support for every motion tabled at its 2025 annual shareholders’ meeting (ASM) held on 29 June 2026 in Suzhou, Jiangsu.\nThe poll-based voting covered six ordinary resolutions, each receiving 17.10 million votes in favour—representing 100.00% of votes cast and 32.68% of the company’s total issued share capital. No votes were recorded against or as abstentions.\nKey resolutions approved:  \n• 2025 work report of the Board of Directors.  \n• 2025 performance report of independent non-executive directors.  \n• 2025 annual financial report.  \n• 2025 profit distribution plan.  \n• Remuneration plan for the current Board session.  \n• Engagement of the Company’s auditor for FY 2026.\nAs at the meeting date, TenNor had 52.33 million H shares in issue, with no treasury shares outstanding.\nExecutive Director and Chairman Dr. Ma Zhenkun presided over the meeting; attending directors included Dr. Song Gaoguang, Dr. Li Leping and Dr. Ni Lin. Independent non-executive director Mr. Lee Wai Kong, Albert was absent due to official duties. Tricor Investor Services Limited and two shareholder representatives acted as scrutineers, validating the poll results.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1162988284","isCrawlerRequest":true}